"1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0"@en . . "Caspofungin inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase."@en . . . . . . . "For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies."@en . . . . "162808-62-0"@en . . . "After single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine."@en . . . . . . . "Johannes Ludescher, Ingolf Macher, Ole Storm, Stephan Bertel, \"Process and Intermediates for the Synthesis of Caspofungin.\" U.S. Patent US20080319162, issued December 25, 2008."@en . . "92% tissue distribution within 36-48 hours after intravenous infusion"@en . . . . . "Caspofungin (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting \u03B2(1,3)-D-Glucan of the fungal cell wall. Caspofungin is administered intravenously."@en . . . . . . "approved"@en . . "(4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide"@en . . . . . "97%"@en . . . "Side effects include rash, swelling, and nausea (rare)"@en . . . . . . . . " "@en . "* 12 mL/min [After single IV administration]"@en . . "9-11 hours"@en . "Caspofungin"@en . . "# Letscher-Bru, Val\u00E9rie, and Raoul Herbrecht. 2003. Caspofungin: the first representative of a new antifungal class. Journal of Antimicrobial Chemotherapy 51, no. 3 (March 1): 513 -521. \"doi:10.1093/jac/dkg117\":http://dx.doi.org/10.1093/jac/dkg117. # Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. Epub 2009 Sep 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19724014 # Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16207161 # McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16162025 # Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16960253 # Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16990627"@en . . . . . . . . . "Aspergillis, Candida and other fungi"@en . . . . . . . " "@en .